

Table S1. Patient demographics and characteristics of treatment with VDZ.

		n	%	average	sd	p-value
female		47	49.5			
male		48	50.5			
CD		23	24.2			
UC		65	68.4			
CI		7	7.4			
age at diagnosis				30.87	14.68	
age at start of VDZ therapy				41	15.28	
disease duration at start of VDZ [years]				10.5	9	
duration of VDZ therapy [months]				17.8	14.6	
application i.v.		82	86.3			
application s.c.		13	13.7			
additional infusion at week 10		35	36.8			
	CD	12	34.3			0.217
	UC	22	62.9			
	CI	1	2.9			
escalation of therapy		62	65.3			
re-induction		2	2.1			
under VDZ at last follow up		47	49.5			
discontinuation of VDZ at last follow up		48	50.5			
	primary nonresponder	19	39.6			
	secondary nonresponder	21	43.8			
	patient's decision	8	16.7			

Abbreviation: CD, Crohn's disease; CI, colitis indeterminata; i.v., intravenous; s.c., subcutaneous; sd, standard deviation; UC, ulcerative colitis; VDZ, vedolizumab